Authors
Latest:
Urologist's Perspective: COVID-19 provides tough decisions—and valuable lessonsUrologists and patients show resilience, but we must be better prepared in the future, says urologist R. Jonathan Henderson, MD.
Latest:
iRARC adoption is slow but persistent in bladder cancer"Over the past 10 to 15 years, tremendous efforts have gone into robotic surgical innovation to improve perioperative morbidity for patients with bladder cancer undergoing RC," write Andrew M. Wood, MD, and Nima Almassi, MD.
Latest:
Post-surgery nivolumab boosts disease-free survival in muscle-invasive urothelial carcinomaAdjuvant treatment with the anti–PD-1 immunotherapy significantly extended the time period after primary treatment in which patients had no signs or symptoms of cancer.
Latest:
Race-based adjustment of eGFR: Current opinions and impact on urologic oncology“As other factors such as access to care, socioeconomic conditions, patient preference, and other unknown confounders might have played a role in the observed disparity, it is still unclear whether overestimating the postoperative eGFR of Black patients contributes to the lower use of nephron-sparing approaches in this population,” the authors write.
Latest:
FDA approves talazoparib plus enzalutamide for HRR gene–mutated mCRPCThe approval is based on findings from the phase 3 TALAPRO-2 trial.
Latest:
Reimplantation of Tibial Nerve Stimulation Device (eCoin)OAB experts share their experience with reimplantation of a tibial nerve stimulation device (eCoin).
Latest:
18F-flotufolastat PET alters treatment approach for nearly 90% of patients with recurrent prostate cancer“Treatment based on visualization of 18F-flotufolastat–avid lesions may facilitate optimal targeting of recurrence sites and avoid futile salvage therapy,” said Przemyslaw Twardowski, MD.
Latest:
Future Research and Development of Abiraterone Combination TherapiesIn this video, experts share their opinion on the potential for novel combination therapies involving micronized abiraterone, particularly in conjunction with PARP inhibitors like olaparib or niraparib, as evidenced in clinical trials such as PROpel and MAGNITUDE. Additionally, they highlight other potential novel combinations like abiraterone with prednisolone and enzalutamide (STAMPEDE trial), and the integration of abiraterone in treatments involving radiation and androgen deprivation therapy (ADT).
Latest:
Physician highlights AI’s potential to improve practice efficiency and alleviate burnoutArtificial intelligence can help curate, decipher, and contextualize the enormous and growing amount of digital data that now comprises a patient’s electronic health record, writes Nele Jessel, MD.
Latest:
How the SECURE Act affects inherited IRAsLegislation sets 10-year withdrawal window for nonspouse beneficiaries.
Latest:
FDA accepts IND application for RAG-01 in NMIBCThe clearance of the IND application for RAG-01 will initiate the launch of clinical trials in the US.
Latest:
Dr. Schwen on focal therapies for prostate cancerZeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
Latest:
Artificial intelligence is the new ghost author in urological research“Although the future of AI within science is uncertain, disclosure of the use of AI is an excellent first step to balance academic integrity with disruptive innovation,” the authors write.
Latest:
Nivolumab/Cabozantinib combo continues to show HRQOL benefit in renal cell carcinomaLong-term follow-up from the CheckMate 9ER trial continued to show that first-line treatment with nivolumab plus cabozantinib was associated with a health-related quality-of-life benefit over treatment with sunitinib in patients with advanced renal cell carcinoma .
Latest:
Suffering from Bladder or Pelvic Floor Issues? Here’s How a Urogynecologist Can HelpUrogynecologists focus on female pelvic medicine and reconstructive surgery, handling issues related to the pelvic floor and bladder.
Latest:
Novel FGFR2/3 inhibitor shows promise in solid tumors, including bladder cancerThe novel agent ABSK061 approached a response rate of 40% in patients with advanced solid tumors harboring FGFR2/3 alterations.
Latest:
Is your practice equipped to battle ransomware attacks?3 steps to protect your practice from ransomware.
Latest:
Frontline masitinib combo delays progression in mCRPC with low metastatic involvementAdding the investigational agent masitinib to standard frontline docetaxel significantly reduced the risk of disease progression or death in men with metastatic castration-resistant prostate cancer and baseline alkaline phosphatase levels (ALP) of 250 IU/mL or less.
Latest:
Going “retro”: A perspective on robotic retroperitoneal renal surgeryImprovements in technology have renewed interest in the technique.
Latest:
Management of hormone-naïve oligometastatic prostate cancerGrowing evidence supports the existence of an intermediate metastatic disease state.
Latest:
The Future of Prostate Cancer ImagingProstate cancer experts highlight some closing thoughts and exciting research in progress on prostate cancer imaging.
Latest:
Key Takeaways on Evolving Bladder Cancer Treatment LandscapeThe expert panel concludes its discussion by providing key takeaways on the evolving bladder cancer treatment landscape following ESMO 2023.
Latest:
Integrating video visits into urologic training"Now is the time for programs to leverage their existing telehealth platforms and practices for trainee education while continuing to serve patients," the authors write.
Latest:
Expert shares best practices to improve patient collectionsImproving your patient payment process in 2023 is important to maintain a positive relationship with your patients and with your practice’s bottom line.
Latest:
Tools urologists need to thrive in a value-based worldPractices must embark on a journey that goes beyond new technology.
Latest:
Prednisone may improve total motile count post vasectomy reversalA course of treatment with prednisone may offer improvement in mean total motile count for men who undergo vasectomy reversal and subsequently have partial or complete anastomotic obstruction, according to a recent study.
Latest:
One-tenth of sperm retrievals performed by gynecologistsA recent study is questioning some of the current trends in sperm retrieval practices in private U.S. clinics that treat infertile couples.
Latest:
Study: Many post-op ER visits preventableAbout half of postoperative visits to emergency rooms following urologic surgery could be prevented, but simply improving patient education may not significantly reduce the number of these visits, researchers say.
